XML 28 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On April 30, 2018, the Company announced the commercial launch of Rhopressa^® in the United States. The Company hired a commercial team that includes approximately 100 sales representatives to target approximately 14,000 high prescribing eye care professionals throughout the United States. Rhopressa^® is now in national and regional U.S. pharmaceutical distributors, and patients have access to Rhopressa^® through pharmacies across the United States. As a result, Aerie commenced generating product revenues related to sales of Rhopressa^® in the second quarter of 2018. Rhopressa^® is a once-daily eye drop designed to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension that received FDA approval on December 18, 2017.